1
|
Mutez E, Swiderski M, Devos D, Moreau C, Baille G, Degardin A, Ryckewaert G, Carriere N, Kreisler A, Simonin C, Rouaix N, Tir M, Krystkowiak P, Ramdane N, Génin M, Sablonnière B, Defebvre L, Huin V. Indication for molecular testing by multiplex ligation-dependent probe amplification in parkinsonism. Eur J Neurol 2023; 30:1667-1675. [PMID: 36916668 DOI: 10.1111/ene.15788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2022] [Revised: 03/01/2023] [Accepted: 03/07/2023] [Indexed: 03/16/2023]
Abstract
BACKGROUND The monogenic forms of Parkinson's disease represent less than 10% of familial cases and a still lower frequency of sporadic cases. However, guidelines to orient genetic testing are lacking. We aim to establish the interest of multiplex ligation-dependent probe amplification as a primary screening test and to propose clinical criteria to guide genetic diagnostic tests for patients with suspected Mendelian Parkinson's disease. METHODS We recruited 567 patients with parkinsonism from 547 unrelated families and performed two multiplex ligation-dependent probe amplifications for each. We confirmed all pathogenic G2019S variants in the LRRK2 gene by Sanger sequencing and screened the PRKN gene for a second mutation in cases of one heterozygous structural variant in the PRKN gene. RESULTS The performance of multiplex ligation-dependent probe amplifications was 51/567 (9%) for the entire cohort and included 27 (4.8%) LRRK2 G2019S mutations, 19 (3.4%) PRKN mutations, and 5 (0.9%) SNCA locus duplications. The variables significantly associated with a positive test in the total cohort were North African ancestry (p < 0.0001), female sex (p = 0.004), and younger age at onset (p < 0.0008). CONCLUSIONS Retrospective analysis allowed us to refine our indication criteria: (i) North African ancestry, (ii) an age at onset < 40, or (iii) a familial history of parkinsonism with at least one affected first-degree relative. Our study highlights the interest of MLPA testing for other parkinsonisms cases with a family history, especially for patients with dementia with Lewy bodies or a multiple system atrophy-like phenotype.
Collapse
Affiliation(s)
- E Mutez
- Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog (JPARC) - Lille Neuroscience & Cognition, F-59000, Lille, France.,Department of Neurology, CHU Lille, Expert Center for Parkinson's Disease, Lille, F-59000, France
| | - M Swiderski
- Department of Neurology, CHU Lille, Expert Center for Parkinson's Disease, Lille, F-59000, France
| | - D Devos
- Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog (JPARC) - Lille Neuroscience & Cognition, F-59000, Lille, France.,Department of Neurology, CHU Lille, Expert Center for Parkinson's Disease, Lille, F-59000, France.,Medical Pharmacology Department, Univ Lille, Inserm, CHU Lille, UMR_S1172, Lille, F-59000, France
| | - C Moreau
- Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog (JPARC) - Lille Neuroscience & Cognition, F-59000, Lille, France.,Department of Neurology, CHU Lille, Expert Center for Parkinson's Disease, Lille, F-59000, France
| | - G Baille
- Department of Neurology, CHU Lille, Expert Center for Parkinson's Disease, Lille, F-59000, France
| | - A Degardin
- Department of Neurology, CHU Lille, Expert Center for Parkinson's Disease, Lille, F-59000, France.,Department of Neurology, Hospital Center of Tourcoing, Tourcoing, France
| | - G Ryckewaert
- Department of Neurology, Hospital Center of Valenciennes, Valenciennes, France
| | - N Carriere
- Department of Neurology, CHU Lille, Expert Center for Parkinson's Disease, Lille, F-59000, France
| | - A Kreisler
- Department of Neurology, CHU Lille, Expert Center for Parkinson's Disease, Lille, F-59000, France
| | - C Simonin
- Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog (JPARC) - Lille Neuroscience & Cognition, F-59000, Lille, France
| | - N Rouaix
- Univ. Lille, Inserm, CHU Lille, Department of Toxicology and Genopathies, UF Neurobiology, F-59000, Lille, France
| | - M Tir
- Department of Neurology and Expert Center for Parkinson's Disease, Amiens University Hospital, CHU Amiens-Picardie, F-80000, Amiens, France
| | - P Krystkowiak
- Department of Neurology and Expert Center for Parkinson's Disease, Amiens University Hospital, CHU Amiens-Picardie, F-80000, Amiens, France
| | - N Ramdane
- Univ. Lille, CHU Lille, Department of Biostatistics, F-59000, Lille, France
| | - M Génin
- Univ. Lille, CHU Lille, Department of Biostatistics, F-59000, Lille, France.,Univ. Lille, CHU Lille, ULR 2694 - METRICS : Evaluation des Technologies de Santé et des Pratiques Médicales, F-59000, Lille, France
| | - B Sablonnière
- Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog (JPARC) - Lille Neuroscience & Cognition, F-59000, Lille, France.,Univ. Lille, Inserm, CHU Lille, Department of Toxicology and Genopathies, UF Neurobiology, F-59000, Lille, France
| | - L Defebvre
- Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog (JPARC) - Lille Neuroscience & Cognition, F-59000, Lille, France.,Department of Neurology, CHU Lille, Expert Center for Parkinson's Disease, Lille, F-59000, France
| | - V Huin
- Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog (JPARC) - Lille Neuroscience & Cognition, F-59000, Lille, France.,Univ. Lille, Inserm, CHU Lille, Department of Toxicology and Genopathies, UF Neurobiology, F-59000, Lille, France
| |
Collapse
|